KOD - Kodiak Sciences Inc logo

KOD

Kodiak Sciences Inc

Rev โ€”top 1%5Y
Hold

Kodiak Sciences Inc. develops therapeutics for retinal diseases, focusing on advanced clinical-stage candidates like tarcocimab tedromer for conditions such as diabetic retinopathy and age-related macular degeneration, targeting significant unmet medical needs.

โš•๏ธ Healthcare NASDAQ Listed 2018 $ USD
$1,000 invested 5 years ago โ†’$492today

Score Overview

1 Year
Scoreโ€”
Net Growth-0.30%
Net TrendShrank
Net Income Consistencyโ€”
Rev Growthโ€”
Rev TrendShrank
Revenue Consistencyโ€”
5 Years
Scoreโ€”
Net Growth13.61%
Net Trend40%
Net Income Consistencyโ€”
Rev Growthโ€”
Rev TrendNever
Revenue Consistencyโ€”
All Time
Scoreโ€”
Net Growth-456.58%
Net Trend25%
Net Income Consistency
Rev Growthโ€”
Rev TrendNever
Revenue Consistency

See the full market ranking โ†’

Kodiak Sciences Inc fundamental performance

Across Kodiak Sciences Inc's full reported history, from 2018 to 2025, revenue held from $ 0.00 to $ 0.00 and net income went from -$ 41M to -$ 229M. Revenue increased in 0% of the years measured; net income in 25%.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 43.41โ€”
1 Year2025-08-12
$ 8.52409.51%
5 Years2021-08-12
$ 88.21-50.79%
All Time2018-10-04
$ 10.16327.26%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2026$ 0.00-$ 230M$ 169M
2025$ 0.00-$ 229M$ 209M
2024$ 0.00-$ 176M$ 168M
2023$ 0.00-$ 260M$ 285M
2022$ 0.00-$ 333M$ 478M
2021$ 0.00-$ 266M$ 731M
2020$ 0.00-$ 133M$ 968M
2019$ 0.00-$ 47M$ 336M
IPO2018$ 0.00-$ 41M$ 88M

Explore beyond KOD

You're looking at Kodiak Sciences Inc. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies